Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
May the retirement happen by making History not just by age
Yes, and 4-6 months from now the answer about the NAS listing and the future of SBFM will be much more clear.
My crystal ball (if I had one) says to accumulate slowly and hold on boldly for 4-6 months.
Today will be day 10
If you go here, look at the recent news and what stands out?
https://www.benzinga.com/quote/SBFM/news
Other than the obvious, no news of any kind in 27 days.
Now that’s strange! Every month but September has news.
Don’t worry nothing has changed joe! Other than the pps but the science is still in the same exact spot as a year and a half ago
Exactly! people wanna be provocative and say it’s gonna be pennies, well it is already pennies...it’s 80 pennies, not all of us are morons here ...99 pennies is not enough to save this.
Wild. Not surprising, Benzinga is a group of paid hacks and liars
Have to start considering a delist notification. What are we, near two weeks in?
“If a company trades for 30 consecutive business days below the $1.00 minimum closing bid price requirement, Nasdaq will send a deficiency notice to the company, advising that it has been afforded a "compliance period" of 180 calendar days to regain compliance with the applicable requirements.”
In 4-6 months it will be at pennies. They have nothing, they have made no progress in 10+ years and Slilaty is 70 years old and a con man.
Well I think we'll know a lot more in 4-6 months. That is the window of opportunity to make this company relevant again and comply with the the NAS listing rules. My guess is SBFM management is not planning to let this get delisted.
This is the link to the 2012 Benzinga article. It got posted on September 25, 2022 so I missed that it was 2012. Look closely at the date at the top of the article.
https://www.benzinga.com/12/09/2939157/biotech-stock-breaking-news-sunshine-biopharmas-otcbb-sbfm-lead-compound-adva-27a-rese
They'd go to jail... Simple
I’d imagine having a Fidelity Nasdaq Index Fund (FNCMX) trading below $1.00 would not look good for SBFM.
If I saw SBFM in my Fidelity investment portfolio, I’d seriously question why Fidelity invested part of my money in a sub dollar NASDAQ index fund.
The only good thing that I see is Bridgeway but not at these prices. Really difficult to find anything positive. SBFM has gone into their own “quiet period” after boasting #transparency to share holders.
This fintel image is easier to read.
Red = bad
White = Not really good in this case.
Green = Generally good, we'll see at the next quarterly update on 9-30
Institutional investors have about 45 days to disclose what their position is.
Bridgeway (BRUSX) and Bridgeway Cap (same company) have 568,400 each which accounts for 1,136,800 out of 1,324,194, leaving 187,394 to the rest. The other one, Virtu Financial LLC, has 47,861 shares worth about $40K as of today.
Indeed. If I was Bridgeway Investments with over 1M shares, I’d be on the first plane to their virtual office at 6500 TRANS-CANADA HIGHWAY 4TH FLOOR POINTE-CLAIRE H9R 0A5.
It literally is a “virtual” office complex sold by Regus. Meaning, no office with all that cash. They deduct it as a business expense for a few hundred each month in their filings.
So where’d the $40Million in funding from them go then.
They’d be up lawsuit alley from the institutional investors.
Time will tell.
Any institutional hedge with -100% has left
Negative share count means short (See Blackstone with -45)
Anything with 0 means the position is so small and low, it falls under $1,000, showing a 0.
Add those up and and you’ve got one institution left holding near all of the shares.
9-30 should give a better idea of these investments.
Latest fintel data
File Date Source Investor Type Avg Share Price Paid (Est) Shares Shares Changed
(%) Reported Value
($1000) Value Changed
(%) Port Allocation
(%) Cost Basis
(x1000) Current
Unrealized Gain/Loss
(x1000) Realized
Gain/Loss
(x1000)
2022-08-19 NP BRUSX - Ultra-Small Company Fund Class N 568,400 614 0.7821
2022-08-16 13F Jane Street Group, Llc 0 -100.00 0 -100.00
2022-08-15 13F Bridgeway Capital Management Inc 568,400 614 0.0140
2022-08-15 13F Morgan Stanley 6,867 7 0.0000
2022-08-15 13F Two Sigma Securities, Llc 20,722 58.83 22 -31.25 0.0008
2022-08-15 13F Tower Research Capital LLC (TRC) 8,128 98.97 9 -10.00 0.0002
2022-08-15 13F Armistice Capital, Llc 0 -100.00 0 -100.00
2022-08-12 13F Geode Capital Management, Llc 20,179 0.00 21 -57.14 0.0000
2022-08-12 13F Hudson Bay Capital Management LP 0 -100.00 0 -100.00
2022-08-12 13F Bank Of America Corp /de/ 3,330 4 0.0000
2022-08-12 13F Empery Asset Management, LP 0 -100.00 0 -100.00
2022-08-11 13F Bank Of Montreal /can/ 31,000 40 0.0000
2022-08-10 13F Citigroup Inc 130 0 0.0000
2022-08-10 13F UBS Group AG 1 -99.96 0 -100.00
2022-08-10 13F Signaturefd, Llc 300 0.00 0 -100.00
2022-08-10 13F Advisor Group Holdings, Inc. 7,528 8 0.0000
2022-08-09 13F Proequities, Inc. 0 0 0.0000
2022-08-09 13F Virtu Financial LLC 47,861 242.77 52 52.94 0.0044
2022-08-05 13F Dakota Wealth Management 20,000 22 0.0015
2022-08-04 13F Larson Financial Group LLC 127 0 0.0000
2022-07-29 NP FNCMX - Fidelity Nasdaq Composite Index Fund [click for advisory] 20,179 26 0.0002
2022-07-28 13F National Bank Of Canada /fi/ 1,042 0.00 1 -66.67 0.0000
2022-05-31 NP Blackstone Alternative Investment Funds - Blackstone Alternative Multi-Strategy Fund Class I [click for advisory] Short -45 -0 -0.0000
Showing 1 to 23 of 23 entries
Uplisted, went as high as $8-12, and made it back to pennys, within about 6-7 months.
Got some of those warrants thinking they would be worth 2-3x what I paid as long as SBFM remained above $1.
If it can’t, the warrants become *worthless* if SBFM gets the boot from nasdaq.
Those in pre reverse split, and many longs need $100 or more to break even.
Those in post uplisting aren’t much better.
Yeah. About the general sentiment summed up.
2012 article was dated September 25. Mistake post (my PR scanner listed it as new news from yesterday).
The irony is that it gets one excited for nothing and that was 10 years ago.
Wasn’t sure what was going to happen today but the market has essentially made up its mind, imo.
The point is it doesn't really matter because they have used that "18-24 months" timeline for over 10 years. They said 10 years ago that that was how far away from phase 1 clinical trials and 10 years later they are still saying the same thing.
I think they think it sounds good, but it also allows a long enough time period that most longs eventually drop out of this stock and they can find new suckers to buy in without a large portion of people that have heard their BS to warn new investors that it's a scam.
All the longs eventually abandon the stock and a new round of retail investors see a stock with a low entry pps and take a lotto ticket on this and the company can drop the same nonsense PRs to entice new investors to drive the price up enough to r/s, rinse and repeat.
thx .. just catching up
Yeah...it’s not the date on the PowerPoint, which is undated, it’s on another release I saw... all of this was discussed on stocktwits on Saturday
Why Sep 21 2022 ? Is that officially announced or just publication date we are assuming ?
Which link is from 2012 ?? I can only find the new ones (that you guys are talking about...)
I agree, but I think sadly the new date is September 21, 2022 you can start from there ...everything that’s happened since the up-list, never happened
I don’t understand from which date are they calculating 18-24 months is it from Feb 2022 ?
They need to provide absolute date estimates like 2023 summer / fall ? Relative months is confusing
He likely put it up to show that this company hasn't budged an inch on any of their supposed drugs in over 10 years, so when the company says 18-24 months before they anticipate clinical testing you know that they have been saying that for over 10 years and have never gotten any closer to starting those trials.
Wow, I missed that year and read 2022! Must have been too hopeful for something new. Wonder why mrpenny put that up again? I guess to highlight the 10 year anniversary which we all know. The 2012 publication is all over their website and filings. I should have caught that!
Ha, it showed up as the most recent. Thanks for pointing that out
Whoops, that article was from 2012!
Very interesting development. If SBFM publishes updated cancer study results in October 2022 followed by a timeline (in 2023) for the Phase 1 Clinical study, that should be the needed catalyst for a sustained uptrend.
Here's the journal link to watch for the publication: https://ar.iiarjournals.org/
Make or break:
Biotech Stock Breaking News; Sunshine Biopharma's (OTCBB: SBFM) Lead Compound Adva-27a Research Results to Be Published in ANTICANCER RESEARCH October Issue.
Neither are very well distributed PR's since they are difficult to find. Most likely a big one will come this week with regards to K1.1.
Maybe its great, but they said the same thing in 2011 up to the present date and still nothing. Everything depends on approvals from the FDA & patent office.
This is way different than covid. Covid cut all the red tape. K1.1 is a cancer fighting treatment and it will be a long drawn process that generally takes 10-15 years to complete. These guys might be in their 80s or 90s by then.
9-30-22 is a very important date. That is I believe when, the next filing will be that shows what institutional/retail investors have left, shorted, or if SBFM potentially picked up more with K1.1. I'd look at that information and published results and studies before I believed anything in these PR's.
#transparency, isn't that what they said? Then went quiet. Shareholders really got nothing except another 10-15 year wait.
jmo
Some news came out today and 09/23/2022 | 02:33pm EDT
https://www.marketscreener.com/quote/stock/SUNSHINE-BIOPHARMA-INC-111313819/news/Sunshine-Biopharma-Presentation-ndash-September-2022-41848914/
^^ Sunshine release
https://www.benzinga.com/12/09/2939157/biotech-stock-breaking-news-sunshine-biopharmas-otcbb-sbfm-lead-compound-adva-27a-rese
^^
by Benzinga Staff, Benzinga Contributor
What do you think it means? Green is Green, but is there anything more to Friday's gain?
https://www.defenseworld.net/2022/09/13/450450-shares-in-sunshine-biopharma-inc-nasdaqsbfm-acquired-by-empery-asset-management-lp.html
A material adverse effect usually signals a severe decline in profitability or the possibility that the company's operations or financial position may be seriously compromised. This is a clear signal to investors that there is something wrong.
Materiality: If It Matters, It's Material
A piece of information is material if it is reasonable to expect that the disclosure of that information will impact the company's stock price.
^^
I think this has happened and SBFM is in damage control. All looked good on paper until you see how this company has shifted from pharmaceuticals to vitamins on Amazon.
Institutions have sold off (at least 6) and one has a short position against Sunshine.
So what the heck. No update except for this on 9/20: “If you want to ensure that you have all the essential amino acids that your body needs, buying amino acids online is the best and easiest way to avoid developing…”
Advanomics corp is Dr Slilaty, where he acquired adva-27a that they all have been trying to market for over a decade and apparently failed every step of the way.
Shares owned: 215,014,224 Split adjusted: 2,687,678 Profit: 0
All the other institutional investment funds are junk, except for this one, Bridgeway Capital Management. They hold or held 1,136,800 shares out of 1,324,194
The rest hold approximately 187,394 shares, with one institutional short.
9-30 is a very important date.
Latest fintel. At least two insiders are at 0 shares, and Camille is the only one showing a profit of +13.11%
Insider Avg Profit (%) Shares Owned Split Adjusted
Corp Advanomi 10% Owner - [10%] 215,014,224 2,687,678
Andrew Mark Keller Director - [D] 0 0
Rabi Kiderchah Director - [D] 325,000 1,625
James Daniel Kish Director - [D] 2,500 12
Abderrazzak Merzouki Chief Operating Officer, Director - [D] [O] 23,342,500 116,712
David Natan Director - [D] 0 0
Camille Sebaaly CFO/Secretary - [O] +13.11 144,465 144,465
Slilaty Steve N. Chief Executive Officer, Director - [D] [O] 10,000 10,000
Andrew I Telsey Director - [D] 3,000 15
$4M evaporated from the market cap this week.
My 52 week range is odd: low $0.7010 high: $5,960.00
These institutional investors are of interest to me. Several show few shares with a value of zero, or an extremely low cash value:
Larson Financial Group LLC ownership in US8677814035 / Sunshine Biopharma Inc
Security US8677814035 / Sunshine Biopharma Inc
Institution Larson Financial Group LLC
Latest Disclosed Ownership 127 shares
Latest Disclosed Value $ 0
Related SBFM / Sunshine Biopharma, Inc.
Larson Financial Group LLC ownership in US8677814035 / Sunshine Biopharma Inc
2022-08-04 - Larson Financial Group LLC has filed a 13F-HR form disclosing ownership of 127 shares of Sunshine Biopharma Inc (US:US8677814035) with total holdings valued at $0 USD as of 2022-06-30.
Citigroup Inc ownership in US8677814035 / Sunshine Biopharma Inc
Security US8677814035 / Sunshine Biopharma Inc
Institution Citigroup Inc
Latest Disclosed Ownership 130 shares
Latest Disclosed Value $ 0
Related SBFM / Sunshine Biopharma, Inc.
Signaturefd, Llc ownership in US8677814035 / Sunshine Biopharma Inc
Security US8677814035 / Sunshine Biopharma Inc
Institution Signaturefd, Llc
Latest Disclosed Ownership 300 shares
Latest Disclosed Value $ 0
Related SBFM / Sunshine Biopharma, Inc.
Signaturefd, Llc ownership in US8677814035 / Sunshine Biopharma Inc
2022-08-10 - Signaturefd, Llc has filed a 13F-HR form disclosing ownership of 300 shares of Sunshine Biopharma Inc (US:US8677814035) with total holdings valued at $0 USD as of 2022-06-30. Signaturefd, Llc had filed a previous 13F-HR on 2022-05-02 disclosing 300 shares of Sunshine Biopharma Inc at a value of $1,000 USD. This represents a change in shares of 0.00 percent and a change in value of -100.00 percent during the quarter.
US8677814035 Institutional Ownership and Shareholders - Sunshine Biopharma Inc
Institutional Owners 18 total, 17 long only, 1 short only, 0 long/short - change of 50.00% MRQ
This updated, too.
Institutional market share decreases about every day, according to fintel.io
Date Market Share (%) Funds Flow (%)
2022-09-21 0.0258
2022-09-20 0.0263
2022-09-19 0.0279
2022-09-16 0.0275
2022-09-15 0.0280
2022-09-14 0.0291
2022-09-13 0.0291
2022-09-12 0.0293
2022-09-09 0.0300
2022-09-08 0.0301
2022-09-07 0.0305
2022-09-06 0.0290
2022-09-02 0.0296
2022-09-01 0.0277
2022-08-31 0.0274
2022-08-30 0.0276
2022-08-29 0.0273
2022-08-26 0.0273
2022-08-25 0.0278
2022-08-24 0.0284
Followers
|
760
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
113656
|
Created
|
10/27/08
|
Type
|
Free
|
Moderators |
SUNSHINE BIOPHARMA INC
ANTI CANCER DRUGS
ANTI CORONA VIRUS RESEARCH
SBFM Transfer Agent
Corporate Stock Transfer
3200 Cherry Creek Dr. South
Suite 430
Denver, CO 80209
(303) 282 - 4800 p
(303) 282 - 5800 f
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |